ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >Linagliptin

Linagliptin

Linagliptin Suppliers list
Company Name: HubeiwidelychemicaltechnologyCo.,Ltd
Tel: 18627774460
Email: faith@widelychemical.com
Products Intro: Product Name:Linagliptin
CAS:668270-12-0
Purity:0.99 Package:1kg 25kg 200 kilograms per barrel
Company Name: Jinan Shengqi pharmaceutical Co,Ltd
Tel: 86+18663751872
Email: christine@shengqipharm.com
Products Intro: Product Name:Linagliptin
CAS:668270-12-0
Purity:99% Package:As customer's requirement
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Email: sales04@yibaibiotech.com
Products Intro: Product Name:Linagliptin
CAS:668270-12-0
Purity:99%+ Package:1g;USD|10g;USD|100g;USD|1KG;USD
Company Name: Jinan Ande Pharmaceutical Co.,Ltd.
Tel:
Email: andepharm@163.com
Products Intro: Product Name:Linagliptin
CAS:668270-12-0
Purity:98% Package:1KG;1USD
Company Name: Hangzhou Huarong Pharm Co., Ltd.
Tel: +86-571-86758373
Email: sales@huarongpharm.com
Products Intro: Product Name:Linagliptin
CAS:668270-12-0
Purity:99% Package:25KG;0USD

Lastest Price from Linagliptin manufacturers

  • Linagliptin
  • US $1.00 / KG
  • 2021-10-15
  • CAS:668270-12-0
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 1000
  • Linagliptin
  • US $20.00 / KG
  • 2021-09-26
  • CAS:668270-12-0
  • Min. Order: 100KG
  • Purity: 99.99%
  • Supply Ability: 10000t
  • Linagliptin
  • US $0.00 / KG
  • 2021-09-15
  • CAS:668270-12-0
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 1000KG

Related articles

  • What is Linagliptin?
  • Linagliptin (TrajentaR, TradjentaTM, TrazentaTM, TrayentaTM) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 ....
  • Feb 10,2020
Linagliptin Basic information
Uses Treatment of Type 2 diabetes Pharmacokinetics
Product Name:Linagliptin
Synonyms:linagliptin;8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione;(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione;1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-;Bi 1356;Ondero;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-d
CAS:668270-12-0
MF:C25H28N8O2
MW:472.54
EINECS:1308068-626-2
Product Categories:TRADJENTA;Linagliptin;Amines;API;Pharmaceutical raw material;Inhibitor;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:668270-12-0.mol
Linagliptin Structure
Linagliptin Chemical Properties
Melting point 202 ºC
Boiling point 661.2±65.0 °C(Predicted)
density 1.39
pka10.01±0.20(Predicted)
Safety Information
HS Code 29335990
Hazardous Substances Data668270-12-0(Hazardous Substances Data)
MSDS Information
Linagliptin Usage And Synthesis
Uses

Linagliptin (TrajentaR, TradjentaTM, TrazentaTM, TrayentaTM) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus.

Treatment of Type 2 diabetes

Linagliptin acts to lower blood glucose levels by inhibiting the enzyme DPP-4, thereby preventing the degradation of the incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic peptide) and attenuating postprandial glucose excursions. By selectively targeting DPP-4, linagliptin potentially causes a more physiologically based control of glucose-dependent postprandial glucose excursions and of fasting blood glucose, both of which are mediated by effects of glucose on insulin and glucagon secretion. An advantage of linagliptin is that since incretin-stimulated release of insulin is glucose dependent, linagliptin is associated with a low incidence of hypoglycaemia. Moreover, DPP-4 inhibitors have a low potential for drug-drug interactions (with the exception of saxagliptin, which is metabolized by cytochrome P450 [CYP] 3A4/5), are generally well tolerated and have minimal or neutral effects on bodyweight. 

Pharmacokinetics

Linagliptin shows modest oral bioavailability, and it is rapidly absorbed. The maximum plasma concentration at steady state is reached on average 1.5 hours after administration of linagliptin 5 mg, once daily . Linagliptin half-life is 131 hours. No relevant food effects were observed on the absorption profile of linagliptin. Unlike other DPP-4 inhibitors, linagliptin excretion is not performed by the kidneys, but rather through the enterohepatic system.

DescriptionLinagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4. Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign. After optimizing the activity of the initial micromolar lead, two issues that needed to be addressed were activity for hERG and muscarinic receptor M1. Introduction of a butynyl group at the N7 position of the xanthine ring gave much reduced M1 affinity with no measureable hERG activity. Linagliptin inhibits DPP-4 with an IC50=1 nM and is highly selective (>10,000-fold) against DPP-8 and DPP-9. Linagliptin shows no interactions with CYPs up to 50 mM. The described synthesis of linagliptin starts with 8-bromoxanthine, which is alkylated at the N-7 position to introduce the butyne group, followed by alkylation of the N-1 group to introduce the methyl-quinazoline group. Displacement of the bromide with (R)-Boc-3-amino-piperidine followed by deprotection gives linagliptin. When administered to db/db mice orally, linagliptin dose dependently reduced glucose excursion from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition).
OriginatorBoehringer Ingelheim (United States)
UsesA novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
Usesdipeptidypeptidase inhibitor, antidiabetic
Useshighly potent CD26 inhibitor
UsesLabeled Linagliptin, intended for use as an internal standard for the quantification of Linagliptin by GC- or LC-mass spectrometry.
DefinitionChEBI: A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type I diabetes.
Brand nameTradjenta
Chemical SynthesisThe synthesis of linagliptin began from commercially available 8-bromo-3-methylxanthine (171). Sequential alkylations of guanine derivative 171 at N-7 with butyn-2-yl bromide in the presence of N,N-diisopropylethylamine and N-1 with 2- (chloromethyl)-4-methylquinazoline (173) in the presence of potassium carbonate, yielded N1,N7-dialkylated xanthine 174 in 85% yield. This material was further condensed with (R)-3-Bocaminopiperidine (175) in the presence of potassium carbonate to give aminopurine dione 176 in 88% yield. Finally, the primary amine of 176 was liberated with trifluoroacetic acid in methylene chloride to produce linagliptin (XV) in 91% yield.

Linagliptin Preparation Products And Raw materials
Tag:Linagliptin(668270-12-0) Related Product Information
Linagliptin Impurity 33 Linagliptin Impurity II Linagliptin Impurity 16 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Linagliptin Phthalimide Impurity Linagliptin Dimer Impurity 3 Linagliptin iMpurity E Linagliptin Impurity 18 Linagliptin Diene Impurity Linagliptin impurity 15 Linagliptin Impurity 13 Linagliptin Related Compound C Linagliptin Impurity 30 Linagliptin Impurity 6 TriHCl Linagliptin Impurity K Linagliptin Impurity 14 Linagliptin Impurity 24 Linagliptin Impurity 11